2 weeks Ago By ABMN Staff
American Century Companies Inc. grew its stake in CareDx, Inc ( NASDAQ:CDNA – Free Report ) by 11.5% in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC).
The fund owned 108,366 shares of the company’s stock after acquiring an additional 11,168 shares during the quarter. American Century Companies Inc.’s holdings in CareDx were worth $1,683,000 at the end of the most recent quarter.
Other hedge funds have also modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of CareDx by 4.
4% during the first quarter. Vanguard Group Inc. now owns 4,300,016 shares of the company’s stock worth $45,537,000 after acquiring an additional 180,334 shares during the period.
Bellevue Group AG increased its stake in shares of CareDx by 0.4% during the 4th quarter. Bellevue Group AG now owns 3,954,792 shares of the company’s stock worth $47,458,000 after purchasing an additional 13,994 shares during the last quarter.
Gagnon Securities LLC raised its stake in CareDx by 7.1% in the first quarter. Gagnon Securities LLC now owns 2,245,529 shares of the company’s stock valued at $23,780,000 after buying an additional 149,485 shares during the period.
Bamco Inc. NY bought a new stake in CareDx in the 1st quarter valued at $13,025,000. Finally, Jacobs Levy Equity Management Inc.
lifted its stake in shares of CareDx by 8.7% during the 1st quarter. Jacobs Levy Equity Management Inc.
now owns 1,150,972 shares of the company’s stock worth $12,189,000 after buying an additional 92,363 shares during the last quarter. CareDx Stock Down 0.4 % Shares of CDNA opened at $29.
70 on Monday. The business has a 50-day simple moving average of $27.31 and a two-hundred day simple moving average of $17.
69. CareDx, Inc has a 12-month low of $4.80 and a 12-month high of $34.
84. The stock has a market cap of $1.55 billion, a PE ratio of -8.
68 and a beta of 1.77. Wall Street Analysts Forecast Growth A number of research firms have recently weighed in on CDNA.
Craig Hallum lifted their target price on CareDx from $22.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, August 1st.
The Goldman Sachs Group lifted their price objective on shares of CareDx from $16.00 to $26.00 and gave the stock a “buy” rating in a research note on Thursday, August 1st.
StockNews.com upgraded shares of CareDx from a “hold” rating to a “buy” rating in a research report on Tuesday, September 24th. Wells Fargo & Company started coverage on shares of CareDx in a research report on Tuesday, August 27th.
They issued an “underweight” rating and a $28.00 price target for the company. Finally, BTIG Research raised CareDx from a “neutral” rating to a “buy” rating and set a $40.
00 price target on the stock in a research report on Monday, August 19th. One equities research analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the company. According to data from MarketBeat.
com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $28.80. Check Out Our Latest Report on CareDx Insiders Place Their Bets In other news, insider Alexander L.
Johnson sold 21,557 shares of the business’s stock in a transaction dated Wednesday, August 21st. The stock was sold at an average price of $32.58, for a total value of $702,327.
06. Following the transaction, the insider now directly owns 284,983 shares of the company’s stock, valued at approximately $9,284,746.14.
The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website . In other news, insider Alexander L. Johnson sold 21,557 shares of the firm’s stock in a transaction that occurred on Wednesday, August 21st.
The shares were sold at an average price of $32.58, for a total transaction of $702,327.06.
Following the completion of the sale, the insider now owns 284,983 shares of the company’s stock, valued at approximately $9,284,746.14. The sale was disclosed in a legal filing with the SEC, which is accessible through this link .
Also, insider Alexander L. Johnson sold 34,231 shares of CareDx stock in a transaction on Monday, August 19th. The shares were sold at an average price of $33.
55, for a total transaction of $1,148,450.05. Following the completion of the sale, the insider now directly owns 284,983 shares of the company’s stock, valued at $9,561,179.
65. The disclosure for this sale can be found here . In the last 90 days, insiders sold 91,340 shares of company stock worth $3,025,415.
4.20% of the stock is currently owned by insiders. About CareDx ( Free Report ) CareDx, Inc engages in the discovery, development, and commercialization of diagnostic solutions for transplant patients and caregivers in the United States and internationally.
It also provides AlloSure Kidney, a donor-derived cell-free DNA (dd-cfDNA) solution for kidney transplant patients; AlloMap Heart, a gene expression solution for heart transplant patients; AlloSure Heart, a dd-cfDNA solution for heart transplant patients; and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Featured Articles Want to see what other hedge funds are holding CDNA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for CareDx, Inc ( NASDAQ:CDNA – Free Report ).
Receive News & Ratings for CareDx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CareDx and related companies with MarketBeat.com's FREE daily email newsletter ..
